Finally, ASO-mediated knockdown of PURPL sensitizes HepG2 human HCC cells to treatment with DOX, suggesting that PURPL could serve as a new therapeutic target for reversing DOX resistance in HCC. Here, PURPL is linked to hepatocellular carcinoma.